Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04348435 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
A Phase 2 study, sponsored by Hope Biosciences Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT04348435 is a Phase 2 study that has completed, run by Hope Biosciences Research Foundation. The registered enrollment target is 53 participants.
The verdict
NCT04348435, a Phase 2 study, has completed, sponsored by Hope Biosciences Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Interventions
- BIOLOGICAL HB-adMSCs
- OTHER Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04348435
The ClinicalTrials.gov registry entry for NCT04348435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences Research Foundation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HB-adMSCs is the first listed.
NCT04348435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04348435 about?
NCT04348435 is a clinical study titled "A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.". Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in ...
What is the current status of trial NCT04348435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2020-05-14. Estimated completion is 2021-05-12.
What interventions are being tested in trial NCT04348435?
The interventions under investigation include: HB-adMSCs (BIOLOGICAL), Placebos (OTHER).
Who is sponsoring clinical trial NCT04348435?
This trial is sponsored by Hope Biosciences Research Foundation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.